We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+16.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$593M
AUM Growth
+$248M
Cap. Flow
+$187M
Cap. Flow %
31.46%
Top 10 Hldgs %
30.55%
Holding
100
New
16
Increased
48
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$13.1M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$12.8M
3
NKTR icon
Nektar Therapeutics
NKTR
+$10.4M
4
UHS icon
Universal Health Services
UHS
+$9.62M
5
AMGN icon
Amgen
AMGN
+$9.42M

Top Sells

Rank Stock Value
1
UTI icon
Universal Technical Institute
UTI
+$6.79M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$5.83M
3
GILD icon
Gilead Sciences
GILD
+$4.79M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.37M
5
CELG
Celgene Corp
CELG
+$3.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.68%
2 Financials 0.74%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
76
DELISTED
Dynavax Technologies
DVAX
$2.75M 0.46%
122,835
– –
EW icon
77
Edwards Lifesciences
EW
$51.7B
$2.71M 0.46%
114,000
– –
TNDM icon
78
Tandem Diabetes Care
TNDM
$1.56B
$2.64M 0.44%
20,900
+3,000
+17% +$390K
KITE
79
DELISTED
Kite Pharma, Inc.
KITE
$2.6M 0.44%
45,000
+10,000
+29% +$670K
ENDP
80
DELISTED
Endo International plc
ENDP
$2.4M 0.4%
+26,741
New +$2.24M
EIGR
81
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.27M 0.38%
267
-169
-39% -$1.48M
MYGN icon
82
Myriad Genetics
MYGN
$312M
$2.12M 0.36%
60,000
+10,000
+20% +$358K
ADVM
83
DELISTED
Adverum Biotechnologies
ADVM
$1.74M 0.29%
+4,300
New +$1.82M
LXRX icon
84
Lexicon Pharmaceuticals
LXRX
$1.1B
$1.51M 0.25%
227,829
– –
MRTX
85
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.33M 0.22%
+45,388
New +$1.06M
MTEM
86
DELISTED
Molecular Templates, Inc.
MTEM
$818K 0.14%
1,221
– –
BIND
87
DELISTED
BIND THERAPEUTICS INC
BIND
$733K 0.12%
133,535
– –
CMRX
88
DELISTED
Chimerix, Inc.
CMRX
$535K 0.09%
+14,200
New +$564K
ORI icon
89
Old Republic International
ORI
$10.4B
– –
-70,000
Closed -$2.32M
TMO icon
90
Thermo Fisher Scientific
TMO
$220B
– –
-22,000
Closed -$2.76M
UTI icon
91
Universal Technical Institute
UTI
$1.59B
– –
-61,000
Closed -$6.79M
HTWR
92
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-38,000
Closed -$2.79M
PCYC
93
DELISTED
PHARMACYCLICS INC
PCYC
– –
-18,500
Closed -$2.26M
SLXP
94
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-38,000
Closed -$4.37M
NPSP
95
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-89,000
Closed -$3.18M
COV
96
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
– –
-57,000
Closed -$5.83M
1 2 3
4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2015 Portfolio in Review

As of Q1 2015, Rhenman & Partners Asset Management held 100 positions worth $593M, up 72% from $345M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $187M of net new capital in Q1 2015, opening 16 new positions and adding to 48 existing holdings. Its largest new stake was Universal Health Services: 87,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $4.79M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2015 buy was Universal Health Services: 87,000 shares worth $10.2M.
  • Rhenman & Partners Asset Management added most to Merck in Q1 2015, an estimated $13.1M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2015 reduction was Gilead Sciences, cutting an estimated $4.79M.
  • Rhenman & Partners Asset Management fully exited Universal Technical Institute in Q1 2015, selling an estimated $6.79M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $593M portfolio in Q1 2015.
  • Rhenman & Partners Asset Management opened 16 new positions and closed 11 in Q1 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 72% quarter-over-quarter to $593M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2015, filed 13 May 2015.